CivicaScript, a Utah-based nonprofit company focused on bringing lower-cost generic medicines to US consumers, announced on Tuesday the appointment of Brent J Eberle, RPh, MBA as its new president, effective 30 September.
Eberle currently serves as chief pharmacy officer at Navitus Health Solutions.
Additionally, Eberle has played a significant role in shaping drug policy at both the state and national levels. He testified before the US House of Representatives Energy and Commerce Subcommittee on Health, sharing his expertise on drug pricing, and served on the Wisconsin Governor's Task Force on Reducing Prescription Drug Prices, a bipartisan group focused on addressing the high cost of prescription medications.
Eberle is to replace CivicaScript's first president, Gina Guinasso, JD, who left in June.
Ned McCoy, Civica president and chief executive officer, said: "We are thrilled to have a business and pharmacy executive of Brent's calibre on board to lead CivicaScript on its important next stage of growth. Given CivicaScript's strong member relationship with Navitus, Brent knows the business and embodies the mission – an ideal foundation to hit the ground running."
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets